Treatment for metastatic pancreatic cancer is becoming more personalized, focusing on controlling aggressive disease while considering each patient’s quality of life. Doctors now tailor therapy based on a patient’s ability to tolerate side effects and their tumor’s specific biomarkers, rather than just survival statistics.
The FDA-approved NALIRIFOX (2024) adds a new first-line option alongside FOLFIRINOX and gemcitabine-based regimens. NALIRIFOX may cause less nerve damage due to a lower oxaliplatin dose, making it a better choice for patients with conditions like diabetes or pre-existing neuropathy. Biomarker testing—both inherited and tumor-based—is now essential for identifying mutations such as KRAS, MET, and HRD, which can guide targeted therapy or clinical trial enrollment.
Doctors also assess patients holistically, considering frailty, social support, and the need for early palliative care. Looking ahead, new KRAS inhibitors, precision medicine strategies, and early clinical trial involvement are expected to improve outcomes, even though most current therapies rarely extend survival beyond one year.